ALMS on Nasdaq
ALUMIS INC.
Price unavailable
Last updated Oct 16, 2026.
Overview
Compare with Entrada Therapeutics, Inc., NewAmsterdam Pharma Co N.V. or NextCure, Inc., or pick any stock.
Financials
From the company’s reports to the SEC. Every number links to the filing it came from.
Key numbers, fiscal 2025
What sells
Revenue by product, business segment and region, as the company reports it to the SEC.
Products and services
License brought in 72% of the revenue ALUMIS INC. broke down this way in fiscal 2025.
Products and services by year
| Products and services | 2025 |
|---|---|
| License | $17.4M |
| Collaboration Revenue | $6.7M |
Where the money goes
Where each dollar of revenue went, fiscal 2025
- Research and development98¢$386.0M
- Income tax2¢$8.6M
Out of $24.1M in revenue.2 The company lost money this year.
Financial statements
Every line of the income statement in the latest annual report, as filed.2
| Period ending | 2025-12-31 | 2024-12-31 |
|---|---|---|
| Total revenue | $24.1M | |
| Research and development expenses, including related party expenses of $1,144 and $912 for the years ended December 31, 2025 and 2024, respectively | $386.0M | $265.6M |
| General and administrative expenses | $91.9M | $35.2M |
| Total operating expenses | $477.9M | $300.8M |
| Loss from operations | -$453.8M | -$300.8M |
| Gain on bargain purchase | $187.9M | |
| Interest income | $14.2M | $12.0M |
| Change in fair value of derivative liability | -$5.4M | |
| Other income (expenses), net | -$169.0K | -$93.0K |
| Total other income (expense), net | $201.9M | $6.5M |
| Net loss before income taxes | -$251.9M | -$294.2M |
| Income tax benefit | $8.6M | $0 |
| Net loss | -$243.3M | -$294.2M |
| Unrealized gain (loss) on marketable securities, net | $148.0K | $38.0K |
| Total comprehensive loss | -$243.2M | -$294.2M |
| Net loss per share attributable to common stockholders, basic | -$2.86 | -$10.38 |
| Net loss per share attributable to common stockholders, diluted | -$2.86 | -$10.38 |
| Weighted-average shares of common stock outstanding, basic | 85.0M shares | 28.3M shares |
| Weighted-average shares of common stock outstanding, diluted | 85.0M shares | 28.3M shares |
Every line of the balance sheet in the latest annual report, as filed.2
| Period ending | 2025-12-31 | 2024-12-31 | 2024-06-30 |
|---|---|---|---|
| Cash and cash equivalents | $89.7M | $169.5M | |
| Restricted cash | $82.0K | ||
| Marketable securities | $218.8M | $118.7M | |
| Research and development prepaid expenses | $2.9M | $13.4M | |
| Other prepaid expenses and current assets | $6.7M | $4.5M | |
| Total current assets | $318.2M | $306.2M | |
| Restricted cash, non-current | $1.3M | $1.1M | |
| Property and equipment, net | $18.2M | $21.0M | |
| Intangible assets | $51.0M | ||
| Operating lease right-of-use assets, net | $17.0M | $12.7M | |
| Other assets, non-current | $6.3M | $7.0K | |
| Total assets | $411.9M | $341.0M | |
| Accounts payable | $10.1M | $9.6M | |
| Research and development accrued expenses | $34.8M | $29.1M | |
| Deferred revenue, current | $1.5M | ||
| Other accrued expenses and current liabilities | $22.3M | $10.6M | |
| Operating lease liabilities, current | $4.7M | $1.6M | |
| Total current liabilities | $73.3M | $50.9M | |
| Operating lease liabilities, non-current | $32.2M | $29.2M | |
| Deferred revenue, non-current | $2.6M | ||
| Deferred tax liability | $2.1M | ||
| Share repurchase liability | $123.0K | $813.0K | |
| Other liabilities, non-current | $207.0K | ||
| Total liabilities | $110.6M | $80.9M | |
| Additional paid-in capital | $1.2B | $918.6M | |
| Accumulated other comprehensive income (loss) | $188.0K | $40.0K | |
| Accumulated deficit | -$901.9M | -$658.6M | |
| Total stockholders' equity | $301.3M | $260.1M | |
| Total liabilities and stockholders' equity | $411.9M | $341.0M | |
| Preferred stock, par or stated value per share | $0.00 | $0.00 | $0.00 |
| Preferred stock, shares authorized | 50.0M shares | 50.0M shares | 50.0M shares |
| Preferred stock, shares issued | 0 shares | 0 shares | |
| Preferred stock, shares outstanding | 0 shares | 0 shares |
Cash flow is reported year to date, not quarter by quarter, so there are no separate quarterly figures.
Every line of the cash flow in the latest annual report, as filed.2
| Period ending | 2025-12-31 | 2024-12-31 |
|---|---|---|
| Net loss | -$243.3M | -$294.2M |
| Stock-based compensation | $43.5M | $19.5M |
| Net accretion of discounts on marketable securities | -$5.3M | -$3.7M |
| Depreciation and amortization | $3.5M | $3.2M |
| Non-cash lease expense | $1.7M | $60.0K |
| Loss on disposal of fixed assets | $5.0K | |
| Change in fair value of derivative liability | $5.4M | |
| Gain on bargain purchase in connection with the ACELYRIN Merger | -$187.9M | |
| Impairment of long-lived assets | $529.0K | |
| Research and development prepaid expenses | $11.5M | -$10.8M |
| Other prepaid expenses and other assets | $17.2M | -$2.9M |
| Other assets, non-current | -$5.5M | |
| Accounts payable | -$6.0M | $8.5M |
| Deferred revenue | $4.1M | |
| Research and development accrued expenses | $2.1M | $18.2M |
| Other accrued expenses and current liabilities | $6.0M | $3.5M |
| Operating lease liabilities | -$3.2M | -$1.9M |
| Other liabilities, non-current | $207.0K | |
| Deferred income tax liability | -$8.6M | |
| Net cash used in operating activities | -$369.5M | -$255.1M |
| Maturities of marketable securities | $448.0M | $128.0M |
| Purchases of marketable securities | -$209.2M | -$240.1M |
| Purchases of property and equipment | -$653.0K | -$1.7M |
| Cash, cash equivalents and restricted cash acquired in connection with the ACELYRIN Merger | $49.7M | |
| Net cash provided by (used in) investing activities | $287.9M | -$113.8M |
| Proceeds from issuance of redeemable convertible preferred stock and derivative liability, net of issuance costs | $258.5M | |
| Proceeds from initial public offering, net of underwriter discounts and commissions and other offering costs | $193.3M | |
| Proceeds from a private placement transaction | $40.0M | |
| Proceeds from issuance of common stock upon exercise of stock options | $489.0K | $596.0K |
| Repurchase of common stock shares issued upon early exercised restricted common stock | -$17.0K | -$6.0K |
| Proceeds from issuance of common stock under the 2024 ESPP | $1.6M | |
| Net cash provided by financing activities | $2.1M | $492.4M |
| Net (decrease) increase in cash, cash equivalents and restricted cash | -$79.6M | $123.5M |
| Conversion of 168,489,871 shares of redeemable convertible preferred stock upon the closing of initial public offering | $639.2M | |
| Equity consideration transferred in connection with the ACELYRIN Merger | $238.1M | |
| Vesting of early exercised stock options and unvested restricted shares of common stock | $673.0K | $1.2M |
| Right-of-use assets obtained in exchange for operating lease liabilities | $1.8M | |
| Recognition of derivative liability upon issuance of redeemable convertible preferred stock | $8.9M | |
| Settlement of derivative liability upon issuance of redeemable convertible preferred stock | -$14.3M | |
| Conversion of redeemable convertible preferred stock (in shares) | 168.5M shares |
Former names
- FL2021-001, Inc.Feb 25, 2021 to Mar 19, 20213
Recent filings
- Sep 9, 20264
- Sep 1, 20268-K
- Aug 17, 2026SCHEDULE 13D
- Aug 13, 20268-K
- Aug 13, 202610-Q
- Aug 10, 20268-K
- Aug 6, 2026SCHEDULE 13G
- Aug 5, 20264
- Aug 5, 20264
- Aug 5, 20264
- Aug 5, 20264
- Aug 5, 20264
- Aug 5, 20264
- Jul 27, 2026SCHEDULE 13G
- Jul 8, 20264
Every filing from the last three years, summarized. The full record is on SEC EDGAR.1
Sources
The numbers on this page point here. Each one links to the record it came from.
- 1SEC EDGARALUMIS INC. filings on SEC EDGAR
- 2SEC EDGARALUMIS INC. 10-K for fiscal 2025
- 3SEC EDGARALUMIS INC. filings on SEC EDGAR
- 4SEC EDGARALUMIS INC. 10-K for fiscal 2023
- 5SEC EDGARALUMIS INC. 10-Q for fiscal 2025
- 6SEC EDGARALUMIS INC. 10-Q for fiscal 2025
- 7SEC EDGARALUMIS INC. 10-Q for fiscal 2026
- 8SEC EDGARALUMIS INC. 10-Q for fiscal 2025